| HIV (Pediatric), Pediatric Studies | AI266-913 | An Expanded Access Study of Oral Liquid Efavirenz in the Treatment of Children With HIV Infection | Available |
| HIV (Adult) | AI424-402 | Atazanavir/Ritonavir (ATV/RTV) Once a Day (QD) + Raltegravir (RAL) Twice a Day (BID) Stable Switch Study | Recruiting |
| HIV (Pediatric), Pediatric Studies | AI424-451 | Phase IIIB Pediatric ATV Powder for Oral Use (POU) (PRINCE2) | Recruiting |
| HIV (Pediatric) | AI424-452 | Safety Sudy of Atazanavir Capsules in the Treatment of HIV in Patients Ages 6 - 18 Years | Not yet recruiting |
| Healthy Volunteers | AI443-006 | Study to Assess the Effect of BMS-791325 on the Pharmacokinetics of Midazolam in Healthy Subjects | Not yet recruiting |
| Healthy Volunteers | AI443-011 | Japanese Bridging Study Conducted in the United States | Not yet recruiting |
| Hepatitis C | AI443-014 | Study to Determine the Effectiveness and Safety of a Three Drug Antiviral Combination Therapy to Treat Hepatitis C Virus (HCV) Infected Patients Not Previously Treated With Currently Available Medications | Recruiting |
| Hepatitis C | AI444-026 | Study With PegInterferon Alfa-2a, Ribavirin and BMS-790052 With or Without BMS-650032 for Participants in Some Hepatitis C Virus (HCV) Trials | Recruiting |
| Hepatitis C | AI444-043 | Safety and Efficacy Study of BMS-790052 Plus Peg-Interferon Alfa 2a and Ribavirin in Untreated Hepatitis C Patients Coinfected With HIV Virus | Recruiting |
| Hepatitis C | AI444-046 | Three-year Follow-up Study of Subjects Who Participated in a Previous Asunaprevir (BMS-650032) and/or Daclatasvir (BMS-790052) Chronic Hepatitis C Clinical Trial | Recruiting |
| Hepatitis C | AI444-063 | Pharmacokinetic and Safety Study of Daclatasvir in Patients With Renal Impairment | Recruiting |
| Hepatitis C | AI447-028 | Phase III Hallmark DUAL: ASV+DCV (Nulls/Partials, Intolerants/Ineligibles. Naives) | Recruiting |
| Hepatitis C | AI447-029 | Phase III Hallmark QUAD: ASV+DCV+Peg+Rib (Nulls/Partials) | Recruiting |
| Hepatitis B (Adult) | AI452-005 | Dose Ranging Study of Pegylated Interferon Lambda in Patients With Hepatitis B and Positive for the Hepatitis B e Antigen | Recruiting |
| Hepatitis C | AI452-008 | Safety Study of Pegylated Interferon Lambda Plus Single or 2 Direct Antiviral Agents With Ribavirin | Recruiting |
| Hepatitis C | AI452-016 | Three-year Follow-up Study of Subjects Who Participated in a Previous Lambda (BMS-914143) Chronic Hepatitis C Clinical Trial | Recruiting |
| Hepatitis C | AI452-017 | Safety and Efficacy Study of Pegylated Interferon Lambda With and Without Daclatasvir, Compared to Pegylated Interferon Alfa, Plus Ribavirin in Subjects With Hepatitis C Genotype 2 and 3 | Recruiting |
| Hepatitis C | AI452-020 | Phase 3 Efficacy and Safety Study of Peginterferon Lambda-1a and Ribavirin With Telaprevir | Recruiting |
| Hepatitis C | AI452-021 | Efficacy and Safety Evaluation of a Regimen Consisting of Peginterferon Lambda-1a + Ribavirin + Daclatasvir (Lambda + RBV + DCV) in HCV Genotype 1b Treatment naïve Patients or Prior Relapsers to Peginterferon Alfa + Ribavirin (Alfa + RBV) Therapy | Recruiting |
| Hepatitis C | AI452-030 | Safety and Efficacy Study in Subjects With Chronic HCV and Underlying Mild or Moderate Hemophilia | Recruiting |
| Hepatitis B (Pediatric), Pediatric Studies | AI463-189 | A Phase III Study of the Safety and Efficacy of Entecavir in Pediatric Patients With Chronic HBV-Infection | Recruiting |
| Hepatitis C | AI472-013 | A Follow-up Evaluation for Safety in Subjects Who Participated in a Phase 1 Study With BMS-986094 (INX-08189) | Recruiting |
| Cancer, Breast Cancer | CA180-185 | Randomized Phase II Trial of Letrozole With or Without Dasatinib as First and Second-line Treatment for Hormone Receptor-positive, HER2-negative Post-menopausal Breast Cancer That is Unresectable, Locally Recurrent or Metastatic | Recruiting |
| Cancer, Leukemia (Pediatric), Pediatric Studies | CA180-226 | A Phase II Study of Dasatinib in Children and Adolescents With Newly Diagnosed Chronic Phase CML or With Ph+ Leukemias Resistant or Intolerant to Imatinib | Recruiting |
| Cancer, Leukemia (Adult) | CA180-330 | Studying First Line Treatment of Chronic Myeloid Leukemia (CML) in a Real-world Setting | Recruiting |
| Cancer, Leukemia (Pediatric), Pediatric Studies | CA180-372 | Pediatric Philadelphia Positive Acute Lymphoblastic Leukemia | Recruiting |
| Cancer, Melanoma | CA180-385 | Trial of Dasatinib in Subjects With Advanced Cancers Harboring DDR2 Mutation or Inactivating B-RAF Mutation | Recruiting |
| Cancer, Leukemia (Adult) | CA180-399 | Phase IIb Study of Dasatinib Versus Imatinib in Patients With CML-CP Who Have Not Achieved an Early Optimal Response to Imatinib | Recruiting |
| Cancer, Leukemia (Adult) | CA180-400 | This Study Will be a Phase IV, Open-label, Multicenter Study of Dasatinib in Chronic-Phase Chronic Myeloid Leukemia (CP-CML) Patients With Chronic, Low-grade Non-Hematologic Toxicity to Imatinib | Recruiting |
| Liver Cancer, Cancer | CA182-037 | Phase III Trans-Arterial Chemo-Embolization (TACE) Adjuvant HCC | Recruiting |
| Lung Cancer, Cancer | CA184-104 | Trial in Squamous Non Small Cell Lung Cancer Subjects Comparing Ipilimumab Plus Paclitaxel and Carboplatin Versus Placebo Plus Paclitaxel and Carboplatin | Recruiting |
| Cancer, Melanoma | CA184-143 | A Multi-National, Prospective, Observational Study in Patients With Unresectable or Metastatic Melanoma | Recruiting |
| Lung Cancer, Cancer | CA184-156 | Trial in Extensive-Disease Small Cell Lung Cancer (ED-SCLC) Subjects Comparing Ipilimumab Plus Etoposide and Platinum Therapy to Etoposide and Platinum Therapy Alone | Recruiting |
| Cancer, Gastrointestinal Cancer | CA184-162 | An Efficacy Study in Gastric and Gastroesophageal Junction Cancer Comparing Ipilimumab Versus Standard of Care Immediately Following First Line Chemotherapy | Recruiting |
| Cancer, Melanoma | CA184-169 | Phase 3 Trial in Subjects With Metastatic Melanoma Comparing 3 mg/kg Ipilimumab Versus 10 mg/kg Ipilimumab | Recruiting |
| Cancer, Melanoma | CA184-178 | Phase 2 Study of Ipilimumab in Children and Adolescents (12 to < 18 Years) With Previously Treated or Untreated, Unresectable Stage III or Stage lV Malignant Melanoma | Recruiting |
| Cancer, Ovarian Cancer | CA184-201 | Phase II Study of Ipilimumab Monotherapy in Recurrent Platinum Sensitive Ovarian Cancer Patients | Recruiting |
| Cancer, Melanoma | CA184-240 | Phase II Safety Study of Vemurafenib Followed by Ipilimumab in Subjects With V600 BRAF Mutated Advanced Melanoma | Recruiting |
| Cancer, Melanoma | CA184-243 | Study to Compare the Effect of Ipilimumab Retreatment With Chemotherapy in Advanced Melanoma | Recruiting |
| Cancer, Solid Tumors | CA186-011 | Safety, Tolerability, Pharmacokinetics, and Immunoregulatory Study of Urelumab (BMS-663513) in Subjects With Advanced and/or Metastatic Solid Tumors and Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma | Recruiting |
| Cancer | CA186-017 | Combination Study of Urelumab and Rituximab in Patients With B-cell Non-Hodgkins Lymphoma or CLL | Recruiting |
| Cancer, Multiple Myeloma | CA204-006 | Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma | Recruiting |
| Cancer, Leukemia (Adult) | CA204-008 | Prospective Research Assessment in Multiple Myeloma: An Observational Evaluation (PREAMBLE) | Recruiting |
| Cancer, Multiple Myeloma | CA204-009 | Study of Bortezomib and Dexamethasone With or Without Elotuzumab to Treat Relapsed or Refractory Multiple Myeloma | Recruiting |
| Cancer, Multiple Myeloma | CA204-011 | Biomarker Study of Elotuzumab in High Risk Smoldering Myeloma | Recruiting |
| Cancer, Melanoma | CA209-004 | Dose-escalation Study of Combination BMS-936558 (MDX-1106) and Ipilimumab in Subjects With Unresectable Stage III or Stage IV Malignant Melanoma | Recruiting |
| Kidney Cancer, Cancer | CA209-009 | Phase I Biomarker Study (BMS-936558) | Recruiting |
| Lung Cancer, Cancer | CA209-012 | Study of Nivolumab (BMS-936558) in Combination With Gemcitabine/Cisplatin, Pemetrexed/Cisplatin, Carboplatin/Paclitaxel, Bevacizumab Maintenance, Erlotinib, Ipilimumab or as Monotherapy in First-Line or in Switch Maintenance in Subjects With Stage IIIB/IV Non-small Cell Lung Cancer (NSCLC) | Recruiting |
| Kidney Cancer, Cancer | CA209-016 | Nivolumab (BMS-936558; MDX-1106) in Combination With Sunitinib, Pazopanib, or Ipilimumab in Subjects With Metastatic Renal Cell Carcinoma (RCC) | Recruiting |
| Lung Cancer, Cancer | CA209-017 | Study of BMS-936558 Compared to Docetaxel in Previously Treated Advanced or Metastatic Squamous Cell Non-small Cell Lung Cancer (NSCLC) | Recruiting |
| Kidney Cancer, Cancer | CA209-025 | Study of BMS-936558 vs. Everolimus in Pre-Treated Advanced Or Metastatic Clear-cell RCC | Recruiting |
| Cancer, Melanoma | CA209-037 | A Study to Compare BMS-936558 to the Physician's Choice of Either Dacarbazine or Carboplatin and Paclitaxel in Advanced Melanoma Patients That Have Progressed Following Anti-CTLA-4 Therapy | Recruiting |
| Cancer, Melanoma | CA209-038 | Phase 1 Biomarker Study of Anti-PD-1 in Advanced Melanoma | Recruiting |
| Cancer, Leukemia (Adult), Non Hodgkin's Lymphoma | CA209-039 | Safety Study of Anti-Programmed Death-1 in Hematologic Malignancy | Recruiting |
| Liver Cancer, Cancer | CA209-040 | Multiple Ascending Dose | Recruiting |
| Lung Cancer, Cancer | CA209-057 | Study of BMS-936558 Compared to Docetaxel in Previously Treated Advanced or Metastatic Non-squamous NSCLC | Recruiting |
| Lung Cancer, Cancer | CA209-063 | Study of BMS-936558 in Subjects With Advanced or Metastatic Squamous Cell Non-Small Cell Lung Cancer Who Have Received At Least Two Prior Systemic Regimens | Recruiting |
| Cancer, Leukemia (Adult) | CA212-001 | First in Human Study to Determine the Safety, Tolerability and Preliminary Efficacy of an Anti-CXCR4 Antibody in Subjects With Acute Myelogenous Leukemia and Selected B-cell Cancers | Recruiting |
| Cancer, Multiple Myeloma | CA212-002 | Anti-CXCR4 (BMS-936564) Alone and in Combination With Lenalidomide/Dexamethasone or Bortezomib/Dexamethasone in Relapsed/Refractory Multiple Myeloma | Recruiting |
| Cancer | CA215-001 | Multiple Ascending Dose of BMS-911543 | Recruiting |
| Cancer, Solid Tumors | CA216-001 | Study to Evaluate the Safety and Tolerability of Weekly IV Doses of BMS-906024 in Subjects With Advanced or Metastatic Solid Tumors | Recruiting |
| Cancer, Leukemia (Adult), Non Hodgkin's Lymphoma | CA216-002 | Study to Evaluate the Safety and Tolerability of Weekly Intravenous (IV) Doses of BMS-906024 in Subjects With Acute T-cell Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma | Recruiting |
| Cancer | CA216-003 | Study to Evaluate the Safety and Tolerability of BMS-906024 in Combination With Chemotherapy (Weekly Paclitaxel, 5FU Plus Irinotecan (FOLFIRI) or Carboplatin Plus Paclitaxel) in Subjects With Advanced or Metastatic Solid Tumors | Recruiting |
| Cancer, Melanoma | CA220-007 | Safety Study of IL-21/Ipilimumab Combination in the Treatment of Melanoma | Recruiting |
| Cancer, Solid Tumors | CA220-008 | Safety Study of IL-21/Anti-PD-1 Combination in the Treatment of Solid Tumors | Recruiting |
| Cancer, Solid Tumors | CA223-001 | A Phase I Study of an Anti-KIR Antibody in Combination With an Anti-PD1 Antibody in Patients With Advanced Solid Tumors | Recruiting |
| Cancer | CA223-002 | Safety Study of BMS-986015 (Anti-KIR) in Combination With Ipilimumab in Subjects With Selected Advanced Tumor | Recruiting |
| Depression | CN162-007 | Efficacy and Safety of Fixed Doses of BMS 820836 in the Treatment of Patients With Treatment Resistant Major Depression | Recruiting |
| Depression | CN162-010 | Long-term Safety and Tolerability of BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression | Recruiting |
| Alzheimer’s Disease | CN167-003 | Study to Evaluate the Safety, Tolerability and the Effect of BMS-241027 on Cerebrospinal Fluid Biomarkers in Subjects With Mild Alzheimer's Disease | Recruiting |
| Migraine | CN170-004 | Study to Evaluate the PK of BMS-927711 in Patient With Migraine During Acute Migraine and Non-migraine Condition | Recruiting |
| | CN171-002 | Multiple Ascending-Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of BMS-933043 in Healthy Subjects | Recruiting |
| Diabetes (Pediatric), Pediatric Studies | CV181-058 | Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Saxagliptin as Monotherapy in Pediatric Patients With Type 2 Diabetes | Recruiting |
| Diabetes (Pediatric), Pediatric Studies | CV181-147 | A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Saxagliptin (BMS-477118) in Combination With Metformin IR or Metformin XR in Pediatric Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Alone | Not yet recruiting |
| Diabetes (Pediatric) | CV181-153 | Study of Saxagliptin, 5-Hydroxy Saxagliptin, and Metformin Concentrations/Levels in Pediatric Subjects With T2DM | Not yet recruiting |
| Diabetes (Adult) | CV181-168 | Safety and Efficacy of Saxagliptin in Triple Therapy to Treat Subjects With Type 2 Diabetes | Recruiting |
| Diabetes (Adult) | CV181-169 | Safety and Efficacy of Combination Saxagliptin & Dapagliflozin Added to Metformin to Treat Subjects With Type 2 Diabetes | Recruiting |
| Blood Clots (Pediatric), Pediatric Studies | CV185-077 | Pediatric Catheter-related Thrombosis Imaging Study | Recruiting |
| Diabetes (Adult), Kidney Disease | CV202-010 | Study to Evaluate the Effects of BMS-813160 on Protein Loss in the Urine of Subjects With Type 2 Diabetes and Diabetic Kidney Disease | Not yet recruiting |
| Atherosclerosis | CV206-001 | Single Ascending Dose Safety Study of BMS-962476 in Healthy Subjects and Patients With Elevated Cholesterol on Statins | Recruiting |
| Rheumatoid Arthritis | IM101-226 | Efficacy and Safety of Abatacept Subcutaneous (SC) in Combination With Methotrexate in Adults With Very Early Rheumatoid Arthritis (RA) | Recruiting |
| Rheumatoid Arthritis | IM101-240 | An Observational Registry of Abatacept in Patients With Juvenile Idiopathic Arthritis | Recruiting |
| Lupus, Lupus Nephritis | IM101-291 | Efficacy and Safety Study of Abatacept to Treat Lupus Nephritis | Recruiting |
| Transplantation | IM103-076 | Evaluating Nulojix (Belatacept) Long-Term Safety in Transplant | Recruiting |
| Rheumatoid Arthritis | IM126-004 | Proof-of-Concept Study With BMS-817399 to Treat Moderate to Severe Rheumatoid Arthritis | Recruiting |
| Colitis | IM129-005 | Induction and Maintenance Study of BMS-936557 Patients With Moderate to Severe Ulcerative Colitis | Recruiting |
| Crohn's Disease | IM129-008 | Induction and Maintenance Study of BMS-936557 in Patients With Moderate to Severely Active Crohn's Disease | Recruiting |
| Rheumatoid Arthritis | IM133-004 | Psoriatic Arthritis Dose Ranging Study for BMS-945429 in Subjects Who Are Not Responding to NSAIDs or Non-biologic Disease Modifying Anti-rheumatic Drugs (DMARDs) Therapy | Recruiting |
| Idiopathic Pulmonary Fibrosis, Lung Disease | IM136-003 | Safety and Efficacy of a Lysophosphatidic Acid Receptor Antagonist in Idiopathic Pulmonary Fibrosis | Recruiting |
| Diabetes (Pediatric), Pediatric Studies | MB102-091 | PK Study of Dapagliflozin in Pediatric Subjects With T2DM | Recruiting |
| Diabetes (Adult) | MB102-129 | Safety and Efficacy of Dapagliflozin in Triple Therapy to Treat Subjects With Type 2 Diabetes | Recruiting |